Skip to content

Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial

Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03064672
Enrollment
500
Registered
2017-02-27
Start date
2020-12-31
Completion date
2021-12-31
Last updated
2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GBS

Brief summary

This prospective cohort study aims to determine whether maternal and neonatal outcomes are affected by GBS carrier status in women undergoing transcervical balloon catheter insertion.

Interventions

DEVICEtranscervical Balloon Catheters

induction of labor by transcervical Balloon Catheters insertion

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* During the study period and in the absence of contraindications, women anticipating induction of labor with unripe cervix will be screened for eligibility. * Inclusion criteria are singleton gestation with confirmed cephalic presentation * Gestational age between 37+0/7 and 41+6/7 weeks' * Intact membranes * Reactive non-stress test and Bishop's score \< 6.

Exclusion criteria

* Women less than 18 years, with multiple gestation pregnancies, pregnancies with major fetal anomalies, vaginal infection, intrauterine fetal death and those who were not candidates for vaginal delivery (placenta previa, non-cephalic presentation, planned cesarean delivery).

Design outcomes

Primary

MeasureTime frameDescription
adverse neonatal outcomes2-3 daysthe incidence of composite adverse neonatal outcomes based on the NICE criteria for early detection of neonatal sepsis

Secondary

MeasureTime frameDescription
composite adverse maternal outcomes2-3 dayschorioamnionitis, suspected chorioamnionitis or endometritis, urinary tract infection or sepsis in the peripartum period, prolonged hospital stay, and allergic reaction to antibiotics

Contacts

Primary ContactMyriam Safrai, MD
myriamsafrai@gmail.com972-506998982
Backup ContactHadas Lemberg,, PhD
lhadas@hadassah.org.il972-508946898

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026